An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo

BACKGROUND: Few treatment options exist for patients with metastatic melanoma, resulting in poor prognosis. One standard treatment, dacarbazine (DTIC), shows low response rates ranging from 15 to 25 percent with an 8-month median survival time. The development of targeted therapeutics with novel mec...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Melissa C, Revers, Leigh, Perampalam, Subodini, Wei, Xin, Kiarash, Reza, Green, David E, Abdul-Wahid, Aws, Gariépy, Jean
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828990/
https://www.ncbi.nlm.nih.gov/pubmed/20128926
http://dx.doi.org/10.1186/1476-4598-9-28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828990/
https://www.ncbi.nlm.nih.gov/pubmed/20128926
http://dx.doi.org/10.1186/1476-4598-9-28

Ejemplares similares